Complete Guide to Enhertu Pharmacokinetics
Overview
Enhertu is a Antibody-Drug Conjugate (ADC) used in the Oncology therapeutic area. It is indicated for HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC. Interactive population pharmacokinetics simulator for trastuzumab deruxtecan (T-DXd / ENHERTU). Sequential 2-compartment ADC and 1-compartment released DXd payload model. Covariate effects on CL and volume. Based on Yin et al. Clin Pharmacol Ther 2021.
Mechanism of Action
Enhertu exerts its pharmacological effect by targeting HER2. As a Antibody-Drug Conjugate (ADC), it modulates this target to achieve therapeutic efficacy in HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This Population PK (Sequential 2-CMT ADC + 1-CMT Payload) model for Enhertu characterizes the time-course of drug concentrations following IV Infusion administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Enhertu is administered via the IV Infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC, understanding the pharmacokinetics of Enhertu is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Enhertu pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive Enhertu PK Simulator
Explore Enhertu pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Enhertu?
The elimination half-life of Enhertu depends on patient-specific factors. Use our interactive Enhertu PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Enhertu administered?
Enhertu is administered via the IV Infusion route. It is indicated for HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC. As a Antibody-Drug Conjugate (ADC), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Enhertu?
Key pharmacokinetic parameters for Enhertu include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a Population PK (Sequential 2-CMT ADC + 1-CMT Payload) model to characterize the pharmacokinetics of Enhertu.
Can I simulate Enhertu dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Enhertu PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.